NCT07199959招募中不适用
A Multi-center Retrospective Study of the Mechanism of Acquired Resistance in First Line Treatment of ROS1fusion Positive NSCLC With Entrectinib
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- biomarker profile
研究概览
简要总结
The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is:
what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients?
Tissue or blood samples of participants who have already taken entrectinib as their regular medical care for NSCLC will send for Next gene sequencing for genomic profiles and bioinformatic analysis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old;
- •Histologically or cytologically diagnosed as non-small cell lung cancer (NSCLC);
- •Clinically staged as IIIB-IV, unresectable locally advanced, recurrent, or metastatic NSCLC according to the 8th edition of the AJCC Lung Cancer Staging Manual;
- •ROS1 fusion detected in tissue, cytological, or liquid biopsy specimens (such as plasma, cerebrospinal fluid, pleural effusion, or ascites) through molecular testing methods such as FISH, RT-PCR, NGS, etc.;
- •At least one measurable lesion according to RECIST 1.1 criteria;
- •No prior systemic anti-cancer treatment for locally advanced/metastatic disease (such as chemotherapy, targeted therapy, immunotherapy, anti-angiogenic therapy, etc.); patients who have previously received platinum-based adjuvant/neoadjuvant chemo/radiotherapy or radical chemo/radiotherapy for progressive disease are eligible if disease progression occurs more than 6 months after the last treatment;
- •For patients who have progressed on first-line treatment with entrectinib and have tissue specimens or peripheral blood samples before and after treatment with entrectinib, they may participate in this study;
- •For patients who are currently on first-line treatment with entrectinib and have not yet progressed, if they have tissue specimens or peripheral blood samples before treatment with entrectinib and agree to participate in this study and sign an informed consent form to collect tissue specimens or peripheral blood samples at the time of first treatment follow-up progression, they may participate in this study;
- •For newly diagnosed patients who have not yet received any drug treatment, those who need first-line treatment with entrectinib according to the clinical standard of care, after agreeing to participate in this study and signing an informed consent form, will have tissue specimens or peripheral blood samples collected before treatment with entrectinib, followed by routine drug use and treatment follow-up, and additional tissue specimens or peripheral blood samples will be collected at the time of first treatment follow-up progression;
- •Cooperate with the researchers to provide clinical and pathological data, imaging data, biological specimen collection, follow-up, etc., required for the study process, and agree to use the testing data for this study.
排除标准
- •Patients with mixed small cell lung cancer components.
- •Carrying other clearly druggable targets, such as EGFR sensitive mutations, EGFR exon 20 insertions, ALK fusions, RET fusions, KRAS activating mutations, BRAF V600E mutations, NTRK1/2/3 fusions, ERBB2 exon 20 insertions, MET exon 14 skipping, MET amplification, etc.
- •Having received prior systemic treatment (such as chemotherapy, targeted therapy, immunotherapy, anti-angiogenic therapy, etc.).
- •Suffering from other malignant tumors within the past 5 years, with the exception of those with very low risks of metastasis or death (5-year RFS rate > 90%, such as early-stage prostate cancer, breast cancer, etc.).
- •Having any contraindications to entrectinib treatment.
- •Being unable to understand the informed consent form, unable to cooperate with sample collection and follow-up, or refusing to sign the informed consent form.
结局指标
主要结局
biomarker profile
时间窗: Analysis will occur when all patient samples have collected. From enrollment to the study completion, an average of 2 year.
次要结局
未报告次要终点
研究者
Jialei Wang
Chief physician
Fudan University
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLCNCT06904547Shanghai Chest Hospital100
已完成
不适用
Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal CancerColorectal CancerNCT00984048Jewish General Hospital160
已完成
不适用
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT01276899Jewish General Hospital80
已完成
不适用
Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant RadiotherapyCancer-related FatigueBreast CancerNCT01468766German Cancer Research Center160
招募中
不适用
Analysis of the mechanisms of acquired resistance to molecular-targeted therapy in lung cancer using liquid biopsy of circulating nucleotide acids and circulating tumor cellsung cancerJPRN-UMIN000031472agoya University Hospital40